Maxion Therapeutics Strengthens Leadership with Appointment of Dr. Stefan Härtle as Chief Development Officer
Maxion Therapeutics has appointed Dr. Stefan Härtle as Chief Development Officer, bringing nearly 20 years of pharmaceutical R&D experience to advance the company's KnotBody® platform into clinical trials.
D&D Pharmatech's DD01 Shows Rapid Liver Fat Reduction in MASH Phase 2 Trial, Matching Competitor Results in Quarter of the Time
D&D Pharmatech's DD01 achieved 75.8% of patients with at least 30% liver fat reduction in just 12 weeks, matching Boehringer Ingelheim's servodutide results that required 48 weeks of treatment.
Major PBMs Exclude Humira Biosimilars from 2025 Formularies, Favor Private-Label Products
The three largest U.S. pharmacy benefit managers have excluded nearly all marketed Humira biosimilars from their 2025 standard formularies, marking a dramatic shift from 2024 when eight products were covered.
Saniona Advances Neurological Pipeline with Strategic Partnerships and Strong Financial Position
Saniona secured SEK 115 million through warrant exercise and maintains SEK 261 million in cash, strengthening its financial runway to advance three internal neurological programs to Phase 2 trials.
Ochre Bio Strengthens Leadership with Former Eli Lilly and AstraZeneca Executive as RNA Therapeutics Company Expands
Oxford-based Ochre Bio has appointed Dr. Elaine Sullivan, former VP at Eli Lilly and AstraZeneca, as Senior Independent Non-Executive Director to support the company's RNA therapeutics development for chronic liver disease.
Boehringer Ingelheim Reports Promising Results for SIRP Inhibitors in Cancer Immunotherapy Trials
Boehringer Ingelheim's SIRP inhibitor BI 765063, when combined with PD-1 inhibitor ezabenlimab and cetuximab, showed manageable safety and promising antitumor activity in patients with recurrent/metastatic head and neck cancer.
BioMed X and Boehringer Ingelheim Complete Groundbreaking Schizophrenia Research Project
BioMed X Institute and Boehringer Ingelheim have successfully completed their second neuroscience collaboration focused on schizophrenia, with Boehringer Ingelheim acquiring the research data for further development.
Dual mTORC1/2 Inhibitor BI 860585 Shows Promise in Phase I Breast Cancer Trial
A Phase I study of BI 860585, a novel dual mTORC1/2 inhibitor, demonstrated manageable safety profile and preliminary efficacy in advanced breast cancer patients.
BioMed X and Boehringer Ingelheim Launch Initiative to Revolutionize Retinal Drug Delivery
BioMed X and Boehringer Ingelheim have announced a global call for proposals to develop next-generation intraocular biologics, marking their second research initiative at the XSeed Labs incubator in Ridgefield, Connecticut.
Brainomix's e-Lung AI Technology Validated for Progressive Pulmonary Fibrosis Detection in Boehringer Ingelheim Collaboration
New studies presented at the American Thoracic Society Conference validate Brainomix's FDA-cleared e-Lung technology as a reliable tool for identifying progressive pulmonary fibrosis with greater sensitivity than conventional methods.